Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).

Authors

null

Priyanka Sharma

University of Kansas Medical Center, Westwood, KS

Priyanka Sharma , Vandana G Abramson , Anne O'Dea , Lauren Elizabeth Nye , Ingrid A. Mayer , Gregory James Crane , Manana Elia , Rachel Yoder , Joshua M Staley , Kelsey Schwensen , Karissa Finke , Jaimie Heldstab , Stephanie LaFaver , Micki Prager , Stephen K. Williamson , Milind Phadnis , Gregory A Reed , Bruce F. Kimler , Qamar J. Khan , Andrew K. Godwin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02393794

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1076)

DOI

10.1200/JCO.2021.39.15_suppl.1076

Abstract #

1076

Poster Bd #

Online Only

Abstract Disclosures